Posted by Michael Wonder on 16 Dec 2020
Durect Corporation announces DUR-928 granted FDA fast track designation for treatment of alcoholic hepatitis
16 December 2020 - Durect Corporation today announced that the U.S. FDA has granted fast track designation to DUR-928 for the treatment of alcoholic hepatitis (also known as alcohol-associated hepatitis).
DUR-928 is the lead investigational product candidate in Durect's Epigenetic Regulator program.
